12 months from date of receipt / reconstitution, 2 to 8 °C as supplied
应用 | 稀释度 |
---|---|
ELISA | 12.64-10000 ng/ml |
Fresolimumab is a human monoclonal antibody and an immunomodulator. It is intended for the treatment of idiopathic pulmonary fibrosis (IPF), focal segmental glomerulosclerosis, and cancer (kidney cancer and melanoma). It binds to and inhibits all isoforms of the protein transforming growth factor beta (TGF-β).
Immobilized human TGF-β1 at 0.5 μg/ml (50μL/well) can bind to Fresolimumab with a linear range of 12.46 ng/ml to 10 μg/ml.